This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Quest Diagnostics (DGX) Q2 Earnings Beat Estimates, FY View Up
by Zacks Equity Research
Quest Diagnostics (DGX) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
NextGen (NXGN) Q1 Earnings Top Estimates, Revenues Surge Y/Y
by Zacks Equity Research
NextGen's (NXGN) first-quarter fiscal 2024 results reflect strength in its revenue sources.
Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Acadia Pharmaceuticals (ACAD) and Abbott (ABT) have performed compared to their sector so far this year.
Company News for Jul 21, 2023
by Zacks Equity Research
Companies In The News Are: KMI, UAL, ABT, IBM.
Abbott (ABT) Q2 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Abbott (ABT) delivers better-than-expected earnings and revenues in the second quarter of 2023
Abbott (ABT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.85% and 2.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
5 Big Cap Earnings Charts to Watch This Week
by Tracey Ryniec
We are going to get a good look at the global economy.
2 Medical Stocks to Buy as Earnings Approach
by Shaun Pruitt
Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week's earnings lineup.
Here's Why You Should Add BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Why Abbott (ABT) Might Surprise This Earnings Season
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Stocks to Buy Ahead of Q2 Earnings Next Week
by Nalak Das
We have narrowed our search to five companies that are set to declare second-quarter earnings results next week. These are: GPC, ABT, AN, SNA, PPG.
What's in Store for Abbott Laboratories (ABT) in Q2 Earnings?
by Zacks Equity Research
The recent FDA approvals and growing customer demand for core therapeutic lines is likely to have driven Abbott's (ABT) Q2 performance.
ABT vs. LMAT: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ABT vs. LMAT: Which Stock Is the Better Value Option?
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $107.50, moving +0.45% from the previous trading session.
AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.
Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) receives FDA approval for the AVEIR DR leadless pacemaker system, featuring the proprietary i2i technology.
Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day.
Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems
by Zacks Equity Research
Abbott (ABT) and ADA are going to offer personalized, therapeutic nutrition for diabetes people using CGM systems.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day.